Cargando…

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go

Detalles Bibliográficos
Autor principal:	Assayag, Deborah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328363/ https://www.ncbi.nlm.nih.gov/pubmed/34242150 http://dx.doi.org/10.1513/AnnalsATS.202102-123ED

Ejemplares similares

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Myeloma: A Lot of Progress, Still a Long Way to Go
por: Mikala, Gábor, et al.
Publicado: (2021)

Predicting post-operative pain: Still a long way to go!
por: Trikha, Anjan, et al.
Publicado: (2013)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

From Arterial Stiffness to Heart Failure: Still a Long Way to Go
por: Canepa, Marco, et al.
Publicado: (2015)

The end of HIV: Still a very long way to go, but progress continues
por: Deeks, Steven G., et al.
Publicado: (2017)

Still, Long Way to Go: Current Status and Perspective of Cardiac Rehabilitation in Korea
por: Sung, Jidong
Publicado: (2023)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go Global?
por: Funke-Chambour, Manuela
Publicado: (2020)

Still a Long Way to Go. Editorial for the Special Issue “Understanding Autism Spectrum Disorder”
por: Aguglia, Eugenio, et al.
Publicado: (2021)

Clinical Implication of Colorectal Cancer Stem Cells: Still Has a Long Way to Go
por: Kim, Hungdai
Publicado: (2015)

MicroRNAs as Biomarkers in Corticosteroid-Resistant/Neutrophilic Asthma: Still a Long Way to Go!
por: Ricciardolo, Fabio L. M., et al.
Publicado: (2020)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Biomarker for recurrent immunoglobulin A nephropathy in kidney allografts: promising but still a long way to go
por: Chung, Byung Ha
Publicado: (2021)

Idiopathic CD4+ T lymphocytopenia: Still a long way to understand the disease
por: K, Ghosh
Publicado: (2020)

Leprosy elimination - Still a long way to go
por: Avancini, João, et al.
Publicado: (2020)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

NAC: still the way to go
por: Gupta, Amit K, et al.
Publicado: (2009)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application
por: Na, Kwon Joong, et al.
Publicado: (2020)

Clostridioides difficile Infection, Still a Long Way to Go
por: Kampouri, Eleftheria, et al.
Publicado: (2021)

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Mechanisms of T(reg) Suppression: Still a Long Way to Go
por: Vignali, Dario A. A.
Publicado: (2012)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
por: Mooney, Joshua, et al.
Publicado: (2021)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

Is It Still “Idiopathic”? Features of Autoimmunity in Idiopathic Pulmonary Arterial Hypertension
por: Frech, Tracy M., et al.
Publicado: (2022)

Circulating MicroRNAs for Diagnosis of Acute Pulmonary Embolism: Still a Long Way to Go
por: Sobrero, Matteo, et al.
Publicado: (2022)

Integrated 'Omics in Idiopathic Pulmonary Fibrosis: Where Do We Go from Here?
por: Castaldi, Peter J.
Publicado: (2021)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqktslfhp9pjjt3au2bp4to2fe